Clinical studies
Studies are essential to clinically validate our innovations and ensure they meet the highest standards of care. They allow us to evaluate the effectiveness and reliability of our devices, optimize our solutions using precise data, demonstrate the advantages of our technologies compared to traditional methods, and assess their medico-economic benefits.
Prospective, multicenter – French study
Bladder cancer
VitaDX International
Phase 1: Develop the most effective image processing algorithm, capable of distinguishing cancerous from non-cancerous urothelial bladder cells. Phase 2: Evaluate the diagnostic performance (sensitivity and specificity) of urine analysis using the VisioCyt® Bladder test."
No reuse in progress
Prospective, multicenter – European study
Bladder cancer
VitaDX International
Demonstration of the benefit of the VisioCyt® Bladder solution through comparison with conventional urine cytology for the detection of recurrences in patients under follow-up for high- and very high-risk non–muscle-invasive bladder tumors.
No reuse in progress
Bladder Cancer
Institut Paoli-Calmettes et VitaDX International
Measure the negative predictive value (NPV) and sensitivity of VisioCyt® Bladder in real-world clinical settings.
No reuse in progress
Prospective, multicenter French study
Bladder cancer
Association Française d'Urologie
To deepen knowledge of bladder tumors and to evaluate, in real-world settings, biomarkers that could ultimately reduce unnecessary cystoscopies and improve patient comfort.
No reuse in progress
Bladder cancer
Institut de Cancérologie de Lorraine
To evaluate the VisioCyt® urinary cytology technique combined with FGFR3 mutation analysis in urine for the diagnosis of bladder cancer, compared with the VisioCyt® urinary cytology technique alone.
No reuse in progress
Would you like to participate?
Your participation plays a key role in the development of innovative technologies that improve cancer care.
Data protection
Among the projects listed above, some studies may involve the reuse of data in a new project. If this occurs, you will be informed through the note ‘reuse of data collected from the study’ in the corresponding study sheet.
Unless you object from the outset, your data may be reused and shared for other research projects in the field of health. You may object to this reuse at any time by contacting VitaDx’s Data Protection Officer.
You have the right to access your data, to have them rectified, and to object to their processing in accordance with applicable regulations.
You also have the following rights:
– The right to request restriction of the processing of your data;
– The right to erasure of your data (however, this right may not be exercisable if it would make the conduct of the study impossible or seriously compromise it);
– The right to define general instructions regarding the retention, erasure and disclosure of your data after your death;
– The right to obtain confirmation as to whether or not personal data concerning you are being processed.
If, after contacting us, you consider that your rights have not been respected, you may lodge a complaint with the French Data Protection Authority (CNIL).
As part of a study, if the processing of your data is based on your consent, you also have the right to data portability.
To exercise your rights, you may send your requests to VitaDx’s Data Protection Officer either by email at [email protected] or by post to 28 Rue de Chambéry, 75015 Paris, France.
